NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Alaunos Therapeutics, Inc. TCRT
19 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 5,000.00
Revenue, FY2025 · full 19-year series below
Revenue $M
Net income $M
FY2025 · Revenue 0.0 · Net income -4.2
Compound annual growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−83520 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -84500.0% · Net -83520.0%
ROE
FY2025 · ROE -198.1%
Each USD of equity lost 198 cents this year.
The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | · | · | 0.0 | 0.0 | · | · | · | · |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.2 | −0.1 | −0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | · | · |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.2 | −0.1 | · | · | · | · | · | · | · | · |
| Income tax $B | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.2 | −0.1 | −0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | · | · |
| EPS, diluted $ | −2.20 | −2.92 | −21.97 | −2.61 | −0.37 | −0.38 | −0.70 | 0.96 | −0.53 | −1.32 | −0.96 | −0.31 | −0.66 | −1.22 | −0.97 | −0.71 | −0.33 | · | · |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −198.1 | −111.8 | −20.9 | −78.1 | −86.5 | −73.0 | −130.5 | · | · | −3282.0 | −198.1 | −76.4 | −116.7 | −160.2 | −124.9 | −111.4 | −43.9 | −136.0 | −87.6 |
| Shares out B | 0.00 | 0.00 | 0.00 | 0.02 | 0.22 | 0.21 | 0.18 | 0.16 | 0.14 | 0.13 | 0.13 | 0.10 | 0.10 | 0.08 | 0.07 | 0.05 | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 67 reconciliationsAUDITED
Reconciled in 19 of 19 fiscal years. 9 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007